Abstracts tagged "autoimmune diseases"

Abstract Number: 0252 • ACR Convergence 2024
Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases
Aurélien Chepy¹, Michaël Genin², Louis Terriou³, Cécile Chenivesse⁴, Delphine Staumont-Sallé⁵, Hélène Zéphir⁶, Peggy philippe⁷, Guillaume Lefevre⁸, Sarah Stabler⁹, Eric HACHULLA³, David Launay¹⁰ and Vincent Sobanski³, ¹Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, ²Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, F-59000, France., Lille, France, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille, France, ⁴Centre de Référence Constitutif des Maladies Pulmonaires Rares, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille 59000, France., Lille, France, ⁵Service de dermatologie CHU Lille Université de Lille Lille France., Lille, France, ⁶Department of Neurology, CRC-SEP, CHU of Lille, Lille, France., Lille, France, ⁷Rheumatology Department, Lille University Hospital, Lille, France., Lille, France, ⁸CHU Lille, Institut d’Immunologie, Lille, France., Lille, France, ⁹CHU Lille, Service Universitaire de Maladies Infectieuses, F-59000 Lille, France; Univ. Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Lille, France, ¹⁰CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille Cedex, France
Background/Purpose: Rituximab (RTX) administration in autoimmune diseases (AID) is associated with severe infectious events (SIE). Frequency of SIE and immune reconstitution (B cells, T cells,…
Abstract Number: 0317 • ACR Convergence 2024
Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry
Pablo Moreno-Fresneda¹, Cristina Vadillo-Font², Fredeswinda Romero-Bueno³, Olga Sánchez-Pernaute⁴, Rosalía Laporta⁵, hildegarda Godoy Tundidor⁶, Belén López-Muñiz⁷, Laura Cebrián⁷, Claudia Valenzuela⁸, Irene Llorente-Cubas⁹, Jesús Loarce¹⁰, Juan Rigual¹⁰, Benjamin fernandez-Gutierrez¹¹, M Asuncion Nieto¹ and lydia Abasolo Alcazar¹², ¹Hospital Clínico San Carlos, Madrid, Madrid, Spain, ²Hospital Clinico S Carlos, Madrid, Spain, ³Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁴Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁶Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ⁷Hospital Universitario Infanta Leonor, Madrid, Spain, ⁸ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain, Madrid, Madrid, Spain, ⁹Hospital Universitario de La Princesa, Madrid, Spain, ¹⁰Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ¹¹HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ¹²IdISSC. HCSC, Madrid, Spain
Background/Purpose: Nintedanib and pirfenidone are approved therapies for the management of patients with progressive fibrosing interstitial lung diseases (ILD), including those of autoimmune origin (ILD…
Abstract Number: 0492 • ACR Convergence 2024
A Machine Learning Model for the Early Identification of Rheumatoid Arthritis: Development and Validation
Michael Dreyfuss¹, Yonatan Jenudi², Dan Riesel³, Or Ramni³, Daniel Underberger⁴, Benjamin Getz⁵, Shlomit Steinberg-Koch³, Douglas White⁶ and Elena Myasoedova⁷, ¹Predicta Med, Ramat Gan, Israel, ²[email protected], Ramat Gan, Israel, ³Predicta Med Analytics Ltd., Ramat Gan, Israel, ⁴Predicta Med Analytics Ltd., Bridgeport, CT, ⁵CTO, Ramat Gan, Israel, ⁶Gundersen Health System, Onalaska, WI, ⁷Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis often experience clinically significant delays in diagnosis (Sørensen et al., 2015; Raza et al., 2011). RA can present similarly to…
Abstract Number: 0733 • ACR Convergence 2024
Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)
Sai Shanmukha Sreeram Pannala¹, fares Saliba², Medha Rajamanuri³ and Veena Katikineni⁴, ¹Staten Island University Hospital, Northwell Health, staten island, new york city, NY, ²Staten Island University Hospital, Staten Island, NY, ³Southern Illinois University School of Medicine, Springfield, IL, ⁴Providence, Victorville, CA
Background/Purpose: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare autoimmune conditions characterized by inflammation of blood vessels, leading to various clinical…
Abstract Number: 0844 • ACR Convergence 2024
Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis
Sheryl Kluberg¹, Sophie E. Mayer², O’Mareen Spence³, Driss Oraichi⁴, Harry Seifert⁴, Omar Ali³, Huifeng Yun⁴, Andrew L. Simon⁵, Jenice S. Ko⁶, Caroline Hugh⁷, Meg Her⁷, Kathleen Shattuck⁷, Richard Platt⁸, Aziza Jamal-Allial⁹, Djeneba Audrey DJIBO¹⁰, Kimberly Daniels¹¹, Qianli Ma¹², Cheryl N McMahill-Walraven¹⁰, Rachel P. Ogilvie¹³, Kristin Palmsten¹⁴, Mano Selvan¹⁵, Najat Ziyadeh¹⁶, Alexis Ogdie¹⁷ and Michael George¹⁸, ¹Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, ²Harvard Pilgrim Health Care Institute, Durham, ³GSK, Rockville, ⁴GSK, Rockville, MD, ⁵Harvard Pilgrim Healthcare Institute, Boston, MA, ⁶Harvard Pilgrim Health Care Ins􀆟tute, Boston, MA, ⁷Harvard Pilgrim Health Care Institute, Boston, MA, ⁸Harvard Pilgrim Health Care Institute / Harvard Medical School, Boston, MA, ⁹Carelon Research, Elevance Health, Newton, ¹⁰CVS Health, Blue Bell, ¹¹Carelon Research, Elevance Health, Wilmington, ¹²Humana Healthcare Research, Inc., Louisville, ¹³Optum, Boston, MA, ¹⁴HealthPartners Institute, Minneapolis, ¹⁵Humana Healthcare Research, Sugar Land, Texas, ¹⁶Optum, Baltimore, MD, ¹⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: The recombinant zoster vaccine (RZV) is US Food and Drug Administration-approved for the prevention of herpes zoster (HZ, shingles) in adults ≥50 years, and…
Abstract Number: 0931 • ACR Convergence 2024
Salivary Granular Convoluted Tubules Contribute to Maintain Tissue-specific Tolerance – Implications for the Development of Murine Sjögren´s Syndrome
Xiaomei Shan¹, Clara Reichardt¹, Marco Munoz Becerra¹, Aleix Rigau², Lena Müller³, Anne Zeitler¹, Jasmin Knopf⁴, Gerhard Grossmayer¹, Martin Herrmann¹, Christine Schauer¹, Markus Eckstein⁵, Georg Schett⁶ and Luis Munoz⁷, ¹Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany, ²Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Medizin Universität Wien, Vienna, Austria, ⁴Universitätsklinikum Mannheim, Mannheim, Germany, ⁵Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁷Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen
Background/Purpose: Primary Sjögren's syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands with an important systemic autoimmune reaction against some nuclear and membrane bound…
Abstract Number: 1044 • ACR Convergence 2024
Analysis of Rheumatic Patients’ Self – Reported Symptoms in Free Written Text Using Natural Language Processing
Inés Pérez - Sancristóbal¹, Nils Steinz², Ling Qin², Tjardo Maarseveen³, Floor Zegers⁴ and Rachel Knevel², ¹Department of Rheumatology, Hospital Clinico San Carlos,, Madrid, Madrid, Spain, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Wormerveer, Netherlands, ⁴Deparment of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patient-reported symptoms are crucial for medical anamnesis. Digital symptom checkers often use fixed questions, thereby potentially overlooking relevant symptoms. However, the reliability of self-reported…
Abstract Number: 1244 • ACR Convergence 2024
Creation of a New Patient-reported Outcome for a Combined Response Index for Limited Cutaneous SSc Using the FDA Guidance on Patient Reported Outcome Measures: The CRISTAL PRO
Alain Lescoat¹, Yen Chen², Rosemary Gedert², Neda Kortam², Nadia Vann², David Cella³, Sara Shaunfield⁴, Susan Murphy⁵ and Dinesh Khanna², ¹CHU Rennes - University Rennes 1, Rennes, France, ²University of Michigan, Ann Arbor, MI, ³Northwestern University, Chicago, IL, ⁴Northwestern University, Chicago, ⁵University of Michigan, Plymouth, MI
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures to assess symptoms that…
Abstract Number: 1492 • ACR Convergence 2024
Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE
Edward Vital¹, Richard Furie², Eric Morand³, Ian Bruce⁴, Jacob Knagenhjelm⁵ and Catharina Lindholm⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, ²Northwell Health, Manhasset, NY, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ⁴Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁵BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: SLE is a chronic disease in which irreversible organ damage can accumulate over time; treatments associated with rapid responses in patients are therefore desirable.1…
Abstract Number: 1651 • ACR Convergence 2024
Unlocking the Secrets of Breg Dysfunction in Lupus: Glycosylation Patterns as Therapeutic Targets
Pauline Kerleroux-Trébaol¹, Marie Morel¹, Sandrine Jousse-Joulin², Divi Cornec³, Pierre Pochard¹ and Anne Bordron¹, ¹Université de Bretagne Occidentale, brest, France, ²cavale blanche hospital, brest, France, ³Service de Rhumatologie, CHU de Brest, Brest, France
Background/Purpose: The immune system is a complex network of cells preventing the invasion of the organism from external particles. The break in the homeostasis will…
Abstract Number: 1783 • ACR Convergence 2024
Deciphering the Roles of Mitochondrial-Related Genes and Ferroptosis in Systemic Lupus Erythematosus: Integrated Analysis for Diagnostic Biomarker Identification and Therapeutic Insights
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Understanding the molecular mechanisms of SLE is crucial for developing effective…
Abstract Number: 1854 • ACR Convergence 2024
TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases
Christopher VanDeusen¹, Shannon Dwyer², Aldo Borroto³, Andres Gagete¹, D Scott Batty Jr¹ and Balbino Alarcon³, ¹Artax Biopharma, Inc, Cambridge, MA, ²Artax Biopharma, Inc., Cambridge, ³Centro de Biología Molecular Severo Ochoa, Madrid, Spain
Background/Purpose: Loss of T-cell tolerance to self-antigens underlies the development of all autoimmune diseases, and despite progress, there remains a significant unmet need for patients.…
Abstract Number: 1980 • ACR Convergence 2024
Efficacy and Safety of Methotrexate in Immune Checkpoint Inhibitor-induced Arthritis: A Retrospective Longitudinal Monocentric Study
Elvis Hysa¹, Andrea Casabella², Nicola Iandolino³, Emanuele Gotelli⁴, Carlo Genova³, Enrica Teresa Tanda³, Carmen Pizzorni⁵, vanessa smith⁶, Alberto Sulli⁷, Maurizio Cutolo⁴ and Sabrina Paolino⁸, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ²Ospedale Policlinico San Martino, Genoa, Italy, ³University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ⁵Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy, ⁸Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (Di.M.I.), University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy
Background/Purpose: The management of immune-mediated adverse events (irAEs) during treatment with immune checkpoint inhibitors (ICIs) involves high dosages of glucocorticoids (GCs). Despite being effective in…
Abstract Number: 2084 • ACR Convergence 2024
Efficacy and Safety of a Step-down Regimen of Low Dosage of Glucocorticoids Combined with Early Administration of Synthetic or Biologic Immunosuppressants in Anti-synthetase Syndrome: A Pilot Study
Edoardo Conticini¹, Paolo Cameli¹, Silvia Grazzini¹, Miriana d'Alessandro¹, Laura Bergantini¹, Brunetta Porcelli¹, Maria Antonietta Mazzei¹, Luca Cantarini¹, Elena Bargagli¹ and Bruno Frediani², ¹Università di Siena, Siena, Italy, ²Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
Background/Purpose: Anti-synthetase syndrome (ASS) is a rare autoimmune disease characterized by the presence of anti-aminoacyl-transfer-RNA synthetase antibodies (ARS) and the involvement of muscles, skin, joints,…
Abstract Number: 2405 • ACR Convergence 2024
Chat-GPT Performance in Diagnosis of Rheumatological Diseases: A Comparison with Specialist’s Opinion
Lucas Goncalves¹ and Carlos Antonio Moura², ¹Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil, ²Bahiana School of Medicine and Public Health, Santo Antonio's Hospital, Sister Dulce's Social Works, Universidade Salvador (UNIFACS), Salvador, Bahia, Brazil
Background/Purpose: Despite Generative Pretrained Transformer Chat (Chat-GPT) is an artificial intelligence tool with the potential to assist doctors in diagnosing and treating patients, little is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].